Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025)

Candel Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 122.08% for Q4 2023.

  • On a quarterly basis, Return on Capital Employed fell 7624.0% to 122.08% in Q4 2023 year-over-year; TTM through Dec 2023 was 122.08%, a 7624.0% decrease, with the full-year FY2023 number at 84.82%, down 4021.0% from a year prior.
  • Return on Capital Employed hit 122.08% in Q4 2023 for Candel Therapeutics, down from 82.11% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CADL hit a ceiling of 29.5% in Q4 2021 and a floor of 122.08% in Q4 2023.
  • Historically, Return on Capital Employed has averaged 55.04% across 3 years, with a median of 43.56% in 2022.
  • Biggest five-year swings in Return on Capital Employed: crashed -37bps in 2022 and later plummeted -7624bps in 2023.
  • Tracing CADL's Return on Capital Employed over 3 years: stood at 29.5% in 2021, then plummeted by -55bps to 45.85% in 2022, then crashed by -166bps to 122.08% in 2023.
  • Business Quant data shows Return on Capital Employed for CADL at 122.08% in Q4 2023, 82.11% in Q3 2023, and 66.04% in Q2 2023.